NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...

The agreement with NanoVation marks the second big recent deal that a B.C. biotech startup has struck with the Danish ...

Canada’s NanoVation Therapeutics has partnered with Novo Nordisk to advance genetic medicines for cardiometabolic and rare ...

ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology ...

NanoVation Therapeutics, a Vancouver company co-founded by biotech magnate Pieter Cullis, has struck a partnership with ...

NanoVation will receive research funding and is eligible to receive up to approximately US$600 million in up-front cash and potential milestone payments, as well as tiered royalties on future product ...

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

ME Therapeutics to begin testing of first mRNA formulations from NanoVation Therapeutics collaboration: Vancouver, British Columbia Friday, September 20, 2024, 14:00 Hrs [IST] ME ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--NanoVation Therapeutics, a platform company developing innovative technologies to overcome the barriers of nucleic acid delivery, today announced a ...